SPOTLIGHT: FDA to give Humira priority review for Crohn's

Abbott Laboratories says that the FDA will give its anti-inflammatory drug Humira a priority review as a treatment for Crohn's disease. The priority review will move up a decision on Humira into early March, cutting four months off the timetable. To back up its application for Humira, Abbott submitted data from a trial of volunteers who had not responded to the monoclonal antibody Remicade (infliximab) made by Centocor. In Crohn's disease inflammation of the digestive tract causes pain and diarrhea. Humira has already been approved for rheumatoid arthritis and other conditions. Report